Mr. Richard Muruve reports

ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT

Arch Biopartners Inc. has closed a non-brokered private placement offering of 145,000 common shares priced at $1.55 per common share and 90,000 common shares priced at $1.15 (U.S.) for total gross proceeds of $374,000.

The final amount of the offering was an increase of $24,000 from the amount originally disclosed to the market on March 5, 2025. The proceeds of the offering will be used by Arch as general working capital and for certain research expenses. The offering is subject to certain conditions including, but not limited to, the receipt of applicable regulatory approvals, including final approval from the TSX Venture Exchange.

All common shares issued in connection with the offering will be subject to a hold period of four months and one day from the closing date. There are finders' fees totalling $5,425 to be paid to arm's-length parties in connection with the offering.

There is no material fact or material change about the company that has not been generally disclosed.

About Arch Biopartners Inc.

Arch Biopartners is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway prevalent in the kidneys, lungs and liver.

Its lead drug candidates, LSALT peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins, respectively, which are both significant unmet medical needs.

We seek Safe Harbor.